Equities research analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce $59.43 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics reported sales of $120,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 49,425%. The company is scheduled to announce its next earnings results on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $272.00 million for the current financial year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts anticipate that the business will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.

CRSP has been the topic of a number of analyst reports. Oppenheimer raised their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 30th. Finally, Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $69.54.

Shares of NASDAQ:CRSP traded up $1.66 during trading on Wednesday, reaching $72.37. The stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The business has a fifty day moving average price of $54.81 and a 200-day moving average price of $47.38. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00.

In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last quarter. 21.40% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in CRSP. Nikko Asset Management Americas Inc. increased its position in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares in the last quarter. ARK Investment Management LLC grew its stake in Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares in the last quarter. Orbimed Advisors LLC purchased a new position in Crispr Therapeutics in the 3rd quarter worth approximately $21,167,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the last quarter. 49.81% of the stock is currently owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Stock Portfolio Tracker

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)




Source link